NUVB

Nuvation Bio Inc.

4.16

USD

-0.03

-0.72%

Nov 06, 15:59 UTC -5

Closed

After-Market

4.28

+0.12

+2.86%

Nuvation Bio Inc. (NUVB) Earnings

NUVB Earnings Reports

Positive Surprise Ratio

NUVB beat 16 of 23 last estimates.

70%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Nuvation Bio Inc. earnings per share and revenue

On Nov 04, 2026, NUVB reported earnings of -0.12 USD per share (EPS) for Q3 26, beating the estimate of -0.12 USD, resulting in a 4.15% surprise. Revenue reached 44.95 million, compared to an expected 34.91 million, with a 28.77% difference. The market reacted with a -11.42% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Novavax Inc

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.34

Actual

-$0.19

Surprise

+44.56%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.31

Actual

$1.06

Surprise

+232.50%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Monte Rosa Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.29

Actual

$0.03

Surprise

+110.09%

PUMA BIOTECHNOLOGY INC

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.15

Surprise

+63.40%

Allogene Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.15

Actual

-$0.15

Surprise

+0.33%

Arcturus Therapeutics Holdings Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.69

Actual

-$0.26

Surprise

+62.44%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

$0.28

Surprise

+373.86%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Vera Therapeutics, Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.65

Actual

-$1.30

Surprise

+21.33%

FAQ

What were Nuvation Bio Inc.'s earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Nuvation Bio Inc. reported EPS of -$0.12, beating estimates by 4.15%, and revenue of $44.95M, 28.77% above expectations.

How did the market react to Nuvation Bio Inc.'s Q3 2026 earnings?

The stock price moved down -11.42%, changed from $4.73 before the earnings release to $4.19 the day after.

When is Nuvation Bio Inc. expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Nuvation Bio Inc.'s next earnings report?

Based on -- analysts, Nuvation Bio Inc. is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.